A major breakthrough towards a targeted therapy of HCC was the discovery that the tumour suppressor DLC1 is deleted in 50% of liver cancers (Xue et al, 2008; Yuan et al, 1998). Here, DLC1 is linked to hepatocellular carcinoma.